Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Total Current Liabilities (2019 - 2025)

Strata Critical Medical (SRTA) has disclosed Total Current Liabilities for 7 consecutive years, with $19.8 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 12.9% to $19.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.8 million through Dec 2025, down 12.9% year-over-year, with the annual reading at $19.8 million for FY2025, 12.9% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $19.8 million at Strata Critical Medical, down from $27.9 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $35.5 million in Q4 2023, with the low at $1.5 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $21.7 million, with a median of $23.0 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities soared 3171.06% in 2021, then tumbled 35.97% in 2024.
  • Over 5 years, Total Current Liabilities stood at $12.8 million in 2021, then soared by 108.14% to $26.6 million in 2022, then soared by 33.39% to $35.5 million in 2023, then crashed by 35.97% to $22.7 million in 2024, then fell by 12.9% to $19.8 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $19.8 million, $27.9 million, and $26.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.